Protective antitumor immunity induced by immunization with completely allogeneic tumor cells

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Previous studies demonstrated that immunization with syngeneic adenovirus type 5 early region 1 (Ad5E1)-transformed tumor cells induces a specific cytotoxic T lymphocyte (CTL) response.
• The H-2Db-restricted CTL response targets an E1B-encoded CTL epitope.

Purpose of the Study:

• To investigate the efficacy of using completely allogeneic tumor cells, engineered with Ad5E1, for inducing anti-tumor immunity.
• To determine if an allogeneic response would impede the induction of a specific anti-tumor CTL response.

Main Methods:

• Mice were immunized with Ad5E1-transformed tumor cells from a different genetic strain (BALB/c, H-2d) than the host (B6, H-2b).
• CTL responses were analyzed, focusing on the recognition of E1B-encoded epitopes presented by H-2Db.
• Mice were subsequently challenged with syngeneic B6 Ad5E1-expressing tumor cells to assess protective immunity.

Main Results:

• Immunization with allogeneic Ad5E1-transformed tumor cells induced a robust CTL response against the E1B-encoded epitope presented by H-2Db.
• The induction of a B6 anti-BALB/c allo-response did not inhibit the development of the anti-E1B CTL response.
• Mice vaccinated with allogeneic Ad5E1 cells were protected against a challenge with syngeneic B6 Ad5E1-expressing tumor cells, unlike those vaccinated with untransformed allogeneic cells.

Conclusions:

• Immunization with completely allogeneic tumor cells engineered with Ad5E1 can effectively induce protective syngeneic anti-tumor immunity.
• Allogeneic tumor cell vaccines are a viable strategy for inducing anti-tumor immunity, overcoming potential overwhelming allogeneic responses.